Albireo Pharma Inc (NASDAQ:ALBO) has received an average rating of “Buy” from the eight brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $51.50.
ALBO has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Albireo Pharma from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Tuesday. ValuEngine raised shares of Albireo Pharma from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 2nd. Cowen reaffirmed a “buy” rating on shares of Albireo Pharma in a report on Wednesday, April 17th. William Blair reaffirmed a “buy” rating on shares of Albireo Pharma in a report on Monday, July 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $62.00 price objective on shares of Albireo Pharma in a report on Sunday.
Shares of NASDAQ ALBO opened at $22.67 on Friday. The business’s fifty day moving average price is $28.29. Albireo Pharma has a 1 year low of $19.10 and a 1 year high of $38.69. The stock has a market capitalization of $286.29 million, a P/E ratio of -5.75 and a beta of 1.52.
Hedge funds and other institutional investors have recently modified their holdings of the company. Marshall Wace North America L.P. acquired a new stake in Albireo Pharma during the first quarter worth about $816,000. Chicago Capital LLC increased its position in Albireo Pharma by 4.7% during the first quarter. Chicago Capital LLC now owns 189,408 shares of the biopharmaceutical company’s stock worth $6,101,000 after purchasing an additional 8,497 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Albireo Pharma by 40.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 116,223 shares of the biopharmaceutical company’s stock worth $2,850,000 after purchasing an additional 33,390 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its position in Albireo Pharma by 356.5% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 3,328 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 2,599 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Albireo Pharma by 7.2% during the fourth quarter. Bank of New York Mellon Corp now owns 37,552 shares of the biopharmaceutical company’s stock worth $921,000 after buying an additional 2,529 shares during the period. Institutional investors and hedge funds own 70.59% of the company’s stock.
About Albireo Pharma
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Recommended Story: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.